- Investing Ideas
- U.S. Pharmaceuticals & Biotech Price disconnect
U.S. Pharmaceuticals & Biotech Price disconnect
Results
23
Stocks which the market has priced substantially different to their cash flows, which could imply risk.
23 companies
Vertex Pharmaceuticals
Market Cap: US$128.2b
Operates as a biotechnology company in the United States, Europe, and internationally.
VRTX
US$515.55
7D
-1.6%
1Y
32.2%
Zoetis
Market Cap: US$30.5b
Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
ZTS
US$72.97
7D
-2.5%
1Y
-52.1%
United Therapeutics
Market Cap: US$21.4b
Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
UTHR
US$508.48
7D
-4.0%
1Y
61.9%
Neurocrine Biosciences
Market Cap: US$15.5b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$154.49
7D
-6.3%
1Y
16.0%
Exelixis
Market Cap: US$12.7b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$52.32
7D
-1.2%
1Y
38.6%
Protagonist Therapeutics
Market Cap: US$10.0b
Operates as a discovery and development company in the United States.
PTGX
US$158.62
7D
5.7%
1Y
182.2%
Krystal Biotech
Market Cap: US$9.8b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$335.73
7D
1.2%
1Y
129.5%
TG Therapeutics
Market Cap: US$6.9b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$49.28
7D
0.2%
1Y
77.7%
Liquidia
Market Cap: US$6.7b
A biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
LQDA
US$77.70
7D
-14.6%
1Y
180.3%
Kiniksa Pharmaceuticals International
Market Cap: US$6.0b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$79.18
7D
3.5%
1Y
134.8%
ACADIA Pharmaceuticals
Market Cap: US$4.9b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$29.01
7D
-1.3%
1Y
15.8%
Indivior Pharmaceuticals
Market Cap: US$4.6b
Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
INDV
US$39.08
7D
1.6%
1Y
66.9%
CareDx
Market Cap: US$2.3b
Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
CDNA
US$46.38
7D
-1.5%
1Y
291.4%
Aurinia Pharmaceuticals
Market Cap: US$2.1b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$15.29
7D
-1.0%
1Y
25.1%
Innoviva
Market Cap: US$1.5b
Operates as a biopharmaceutical company in the United States and internationally.
INVA
US$20.96
7D
1.4%
1Y
0.9%
Phibro Animal Health
Market Cap: US$1.4b
Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.
PAHC
US$34.63
7D
1.4%
1Y
10.8%
Collegium Pharmaceutical
Market Cap: US$919.0m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$28.07
7D
3.2%
1Y
-26.5%
Rigel Pharmaceuticals
Market Cap: US$795.4m
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
RIGL
US$42.45
7D
1.9%
1Y
5.9%
CorMedix
Market Cap: US$587.7m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.67
7D
1.9%
1Y
-41.5%
Compugen
Market Cap: US$228.3m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.35
7D
0.4%
1Y
51.6%
Protalix BioTherapeutics
Market Cap: US$178.9m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.29
7D
-7.7%
1Y
48.7%
Fortress Biotech
Market Cap: US$97.7m
Operates as a biopharmaceutical company in the United States and internationally.
FBIO
US$2.82
7D
2.5%
1Y
25.3%
Bio Essence
Market Cap: US$13.5m
Engages in manufacturing and distributing health supplement products.
BIOE
US$0.25
7D
0%
1Y
163.2%